Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cipher reports fiscal 2009 financial results


      News provided by

      Cipher Pharmaceuticals Inc.

      Feb 17, 2010, 07:00 ET

      Share this article

      Share this article


      Toronto Stock Exchange Symbol: DND

      MISSISSAUGA, ON, Feb. 17 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009.

          
          Fiscal 2009 Summary
          -------------------
      
          -   Total revenue more than doubled to $3.2 million, driven by growth of
              Lipofen(R) prescriptions.
          -   Strong balance sheet at year end with cash of $9.0 million and no
              debt, compared with cash of $9.9 million at December 31, 2008.
          -   Commenced CIP-ISOTRETINOIN Phase III safety trial in Q3; with 176
              patients enrolled at year-end.
          -   Achieved tentative FDA approval for CIP-TRAMADOL ER; subsequent to
              year end, received favourable summary judgment motion relating to
              patent litigation.
          -   Strengthened Board of Directors with the addition of Dr. William
              Claypool.
          
      

      "The continued steady growth of Lipofen(R) prescriptions helped us deliver a strong year-over-year increase in revenue and reduce our cash burn, ensuring that our financial position remains solid," said Larry Andrews, President and CEO of Cipher. "From a clinical perspective, we commenced enrolment on our Phase III safety trial for CIP-ISOTRETINOIN, and this continues to progress well. On the regulatory front, 2009 saw us obtain tentative FDA approval for CIP-TRAMADOL ER. More recently, we received a favourable judgment in pending patent litigation for this product, clearing the way for us to pursue final FDA approval."

          
          Financial Review
          ----------------
          
      

      Total revenue in 2009 was $3.2 million, compared with $1.5 million in 2008. Revenue from Lipofen(R) totalled $2.9 million in 2009, reflecting the continued market penetration by Lipofen(R) as Kowa increases the sales and promotion effort behind the product. Revenue from CIP-ISOTRETINOIN was $0.3 million in 2009, which relates to revenue recognized on the Company's share of the US$1 million upfront milestone payment received from Ranbaxy in 2008.

      Gross Research and Development ("R&D") expenditures for 2009 were $5.4 million, compared with $2.2 million in 2008. The reported R&D amount of $1.0 million for 2009 is net of reimbursements of $4.4 million from Ranbaxy related to the CIP-ISOTRETINOIN clinical study. As previously disclosed, the Company's U.S. marketing partner, Ranbaxy Pharmaceuticals, is reimbursing Cipher for all costs associated with the clinical studies required to obtain FDA approval, up to a predetermined cap. Any additional development costs associated with initial FDA approval will be shared equally.

      Operating, General and Administrative ("OG&A") expenses for 2009 were $4.3 million, compared with $3.6 million in 2008. The year-over-year change reflects the increased level of activity related to pursuing pipeline expansion opportunities. The loss for the 12 months ended December 31, 2009 decreased to $2.7 million ($0.11 per basic and diluted share), compared with a net loss of $3.2 million ($0.13 per basic and diluted share) in 2008.

      In Q4 2009, Cipher recorded licensing revenue of $0.8 million, compared with $0.4 million in Q4 2008. Gross R&D expenditures for the fourth quarter were $3.0 million, and reported R&D expenses were $0.3 million. OG&A expenses for Q4 2009 were $1.1 million, compared with $0.9 million in the same period last year. Loss for the three months ended December 31, 2009 was $0.6 million ($0.03 per basic and diluted share), compared with a loss of $0.5 million ($0.02 per basic and diluted share) in the same period last year.

      The Company's financial position remained solid at year-end. As at December 31, 2009, Cipher had cash of $9.0 million, compared with $9.9 million as at December 31, 2008.

          
          Product Update
          --------------
          
      

      During 2009, Lipofen(R) monthly prescriptions showed steady growth, and Cipher is hopeful that this trend will continue as Kowa increases penetration of the primary care physicians in its targeted regions and expands its sales force. Kowa's sales force reached approximately 200 at the end of the year, and additional increases are expected in Q1 2010 to support the launch of Kowa's pitavastatin product, LIVALO(R), in the second quarter of 2010.

      During Q3 2009, Cipher commenced its Phase III safety trial for CIP-ISOTRETINOIN under a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration ("FDA"). The 800-patient study is a double-blind, randomized trial comparing CIP-ISOTRETINOIN to an FDA-approved, commercially available isotretinoin product. The study is being conducted in the U.S. and Canada over an 18-month period. The study is progressing well, with enrolment reaching 176 patients at year end and currently nearing the mid-point.

      Cipher received tentative FDA approval for CIP-TRAMADOL ER, the Company's extended-release formulation of tramadol, in February 2009. During Q4 2009, the Company announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. Under the applicable provisions of the Hatch-Waxman Act, this patent challenge can delay final FDA approval of Cipher's NDA by 30 months, or until the patent challenge is resolved, whichever occurs first. Subsequent to year end, the Company announced that a final judgment on the above litigation suit has been entered in favour of Cipher. The judgment removes any further stay of FDA approval of Cipher's NDA under the applicable provisions of the Hatch-Waxman Act. Cipher is moving forward to obtain FDA final approval as part of its broader CIP-TRAMADOL ER commercialization strategy.

      The final judgment in favour of Cipher holds that the patents-in-suit are invalid for obviousness based on a prior decision of the United States District Court for the District of Delaware, invalidating the Orange Book-listed patents for Ultram(R) ER in litigation filed by Purdue against Par Pharmaceutical, Inc. ("Par"). That decision in the Par litigation is currently on appeal before the United States Court of Appeals for the Federal Circuit. The Court's decision is not expected until the latter half of 2010. If Par is successful in its appeal, Cipher believes CIP-TRAMADOL ER will no longer face any further risk of litigation from Purdue in connection with the Orange Book-listed patents that were asserted against Cipher.

      Cipher continues to actively pursue new early stage pipeline product candidates and advance out-licensing discussions for its current products.

          
          Notice of Conference Call
          -------------------------
          
      

      Cipher will hold a conference call today, February 17, 2010, at 8:30 a.m. (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. A live audio webcast of the call will be available at www.cipherpharma.com. The webcast will be archived for 90 days.

      About Cipher Pharmaceuticals Inc.

      Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug Administration and Health Canada in the first quarter of 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007).

      Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.

      Forward-Looking Statements

      Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent litigation; regulatory approval of products in the Company's pipeline; changes in government regulation or regulatory approval processes; government and third-party payer reimbursement; dependence on strategic partnerships for product candidates and technologies, marketing and R&D services; meeting projected drug development timelines and goals; intensifying competition; rapid technological change in the pharmaceutical industry; anticipated future losses; the ability to access capital to fund R&D; and the ability to attract and retain key personnel. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

          
          Cipher Pharmaceuticals Inc.
          Balance Sheets
          (in thousands of dollars)
      
                                                                    As at
                                                          December 31, December 31,
                                                              2009         2008
      
          ASSETS
      
          Current assets
          Cash                                            $     9,006  $     9,881
          Accounts receivable                                     967          512
          Income taxes receivable                                   -            6
          Prepaid expenses and other current assets               457          380
          Current portion of loan receivable (note 5)             800          608
          -------------------------------------------------------------------------
                                                               11,230       11,387
      
          Property and equipment, net (note 4)                     86          147
      
          Loan receivable (note 5)                                  -          717
      
          Intangible assets, net (note 6)                       3,507        4,126
      
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
                                                          $    14,823  $    16,377
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          LIABILITIES
      
          Current liabilities
          Accounts payable and accrued liabilities        $     1,570  $     1,178
          Current portion of deferred revenue                   1,956        1,177
          -------------------------------------------------------------------------
                                                                3,526        2,355
      
          Deferred revenue                                        329          994
          -------------------------------------------------------------------------
                                                                3,855        3,349
          -------------------------------------------------------------------------
      
          SHAREHOLDERS' EQUITY
      
          Share capital (note 7)                               49,948       49,948
          Contributed surplus (note 8)                         32,268       31,613
          Deficit                                             (71,248)     (68,533)
          -------------------------------------------------------------------------
                                                               10,968       13,028
          -------------------------------------------------------------------------
      
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
                                                          $    14,823  $    16,377
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          The accompanying notes are an integral part of these financial statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Statements of Operations and Comprehensive Loss
          (in thousands of dollars, except per share amounts)
      
                                                             For the year ended
                                                          December 31, December 31,
                                                              2009         2008
      
          Revenues
            Licensing revenue                             $     3,179  $     1,543
          -------------------------------------------------------------------------
      
          Expenses
            Research and development (note 9)                     956        1,303
            Operating, general and administrative               4,252        3,565
            Amortization of property and equipment                 69           71
            Amortization of intangible assets                     741          466
            Recovery of legal fees and court costs                  -         (176)
            Interest income                                      (124)        (456)
          -------------------------------------------------------------------------
      
                                                                5,894        4,773
          -------------------------------------------------------------------------
      
          Loss and comprehensive loss for the year        $    (2,715) $    (3,230)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
      
          Basic and diluted loss per share (note 11)      $     (0.11) $     (0.13)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          The accompanying notes are an integral part of these financial statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Statements of Deficit
          (in thousands of dollars)
      
                                                             For the year ended
                                                          December 31, December 31,
                                                              2009         2008
      
          Deficit, beginning of year                      $   (68,533) $   (65,303)
      
          Loss for the year                                    (2,715)      (3,230)
          -------------------------------------------------------------------------
      
          Deficit, end of year                            $   (71,248) $   (68,533)
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          The accompanying notes are an integral part of these financial statements
      
      
      
          Cipher Pharmaceuticals Inc.
          Statements of Cash Flows
          (in thousands of dollars)
      
                                                             For the year ended
                                                          December 31, December 31,
                                                              2009         2008
      
          Cash provided by (used in)
      
          Operating activities
            Loss for the year                             $    (2,715) $    (3,230)
            Items not affecting cash
              Amortization of property and equipment               69           71
              Amortization of intangible assets                   741          466
              Stock-based compensation expense                    655          581
              Imputed interest (note 5)                           (87)        (136)
          -------------------------------------------------------------------------
                                                               (1,337)      (2,248)
            Net change in non-cash operating items
             (note 12)                                            (20)         990
            Drawdown of loan receivable                             -          188
          -------------------------------------------------------------------------
      
                                                               (1,357)      (1,070)
          -------------------------------------------------------------------------
      
          Investing activities
            Proceeds from loan receivable (note 5)                612            -
            Acquisition of intangible rights (note 6)            (122)           -
            Purchase of property and equipment                     (8)         (10)
          -------------------------------------------------------------------------
      
                                                                  482          (10)
          -------------------------------------------------------------------------
      
          Decrease in cash                                       (875)      (1,080)
          Cash, beginning of year                               9,881       10,961
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          Cash, end of year                               $     9,006  $     9,881
          -------------------------------------------------------------------------
          -------------------------------------------------------------------------
          The accompanying notes are an integral part of these financial statements
      
      
          Cipher Pharmaceuticals Inc.
          Notes to Financial Statements
          December 31, 2009
          (in thousands of dollars, except per share amounts)
      
          1   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
      
              These financial statements have been prepared in accordance with
              Canadian generally accepted accounting principles. Significant
              accounting policies used in the preparation of these financial
              statements are as follows:
      
              Translation of foreign currencies
      
              Revenues and expenses denominated in foreign currencies are
              translated into Canadian dollars using the exchange rate in effect at
              the transaction date. Monetary assets and liabilities are translated
              using the rate in effect at the balance sheet date and non-monetary
              items are translated at historical exchange rates. Related exchange
              gains and losses are included in the determination of the loss for
              the year.
      
              Use of estimates
      
              The preparation of these financial statements requires management to
              make estimates and assumptions that could affect the reported amounts
              of assets and liabilities at the date of the financial statements and
              the reported amounts of revenues and expenses during the reporting
              periods presented. Significant areas requiring the use of management
              estimates include the valuation of intangible assets and measurement
              of income taxes. By their nature, these estimates are subject to
              measurement uncertainty. Actual results could differ from the
              estimates and assumptions.
      
              Property and equipment
      
              Property and equipment are recorded at cost less accumulated
              amortization. Amortization is computed using the straight-line method
              using the following estimated useful lives of the assets or lease
              terms:
      
                 Computer equipment                                        3 years
                 Computer software                                         3 years
                 Furniture and fixtures                                    5 years
                 Leasehold improvements                 over the term of the lease
      
              Impairment of long-lived assets
      
              Long-lived assets are tested for recoverability whenever events or
              changes in circumstances indicate the carrying value may not be
              recoverable. An impairment loss is recognized when the carrying
              amount of a long-lived asset exceeds the sum of the estimated
              undiscounted cash flows from the long-lived asset. An impairment loss
              is measured as the amount by which the carrying amount of the
              long-lived asset exceeds the estimated fair value.
      
              Intangible assets
      
              Intangible assets consist of marketing and other rights relating to
              products and are initially recorded at cost. Intangible assets have a
              finite life and are amortized using the straight-line method over
              their estimated period of useful life. Amortization commences on the
              earlier of the date of regulatory (generally, U.S. Food and Drug
              Administration ("FDA")) approval for marketing the related product or
              upon substantive revenue being generated from the product under a
              commercial licensing agreement. The estimated period of useful life
              has been determined to be 3.5 years from the date of regulatory
              approval for marketing the related product. Should amortization
              commence as a result of generating revenue, the amortization period
              would include the time prior to regulatory approval. Intangible
              assets are reviewed for impairment when events or other changes in
              circumstances indicate that the carrying amount of the assets may not
              be recoverable.
      
              Revenue recognition
      
              The Company recognizes revenue from product sales contracts and
              licensing and distribution agreements, which may include multiple
              elements. The individual elements of each agreement are divided into
              separate units of accounting, if certain criteria are met. The
              applicable revenue recognition approach is then applied to each unit.
              Otherwise, the applicable revenue recognition criteria are applied to
              combined elements as a single unit of accounting.
      
              Product sales - revenue from product sales contracts is recognized
              when the product is shipped to the Company's customers, at which time
              ownership is transferred.
      
              Licensing revenues - for up-front licensing payments and
              pre-commercialization milestones, revenue is deferred and recognized
              on a straight-line basis over the estimated term that the Company
              maintains substantive contractual obligations. Post-commercialization
              milestone payments are recognized as revenue when the underlying
              condition is met, the milestone is not a condition to future
              deliverables and collectability is reasonably assured. Otherwise,
              these milestone payments are recognized as revenue over the remaining
              term of the underlying agreement or the term over which the Company
              maintains substantive contractual obligations. Royalty revenue is
              recognized in the period in which the Company earns the royalty.
              Amounts received in advance of recognition as revenue are included in
              deferred revenue. Revenue from licensing and distribution agreements
              is presented on a net basis.
      
              Research and development
      
              The Company conducts research and development programs and incurs
              costs related to these activities, including employee compensation,
              materials, professional services and services provided by contract
              research organizations. Research and development costs, net of
              related tax credits, are expensed in the periods in which they are
              incurred.
      
              Income taxes
      
              The Company uses the asset and liability method of accounting for
              income taxes. Under this method, future tax assets and liabilities
              are determined based on differences between the financial reporting
              and income tax bases of assets and liabilities and are measured using
              enacted or substantively enacted tax rates and laws that will be in
              effect when the difference is expected to reverse. The Company
              provides a valuation allowance for future tax assets when it is more
              likely than not that some or all of the future tax assets will not be
              realized.
      
              Stock-based compensation
      
              The fair value of stock options granted after October 1, 2002 is
              recognized as compensation expense on a straight-line basis over the
              applicable stock option vesting period. Stock-based compensation
              expense is included in operating, general and administrative expense
              in the statements of operations and contributed surplus in the
              balance sheets. The consideration received on the exercise of stock
              options is credited to share capital at the time of exercise.
      
              Financial instruments
      
              Financial instruments are measured at fair value except for loans and
              receivables, held-to-maturity investments and other financial
              liabilities, which are measured at cost or amortized cost. Gains and
              losses on held-for-trading financial assets and liabilities are
              recognized in net earnings in the period in which they arise.
              Unrealized gains and losses, including changes in foreign exchange
              rates on available-for-sale financial assets, are recognized in
              comprehensive income until the financial assets are derecognized or
              impaired, at which time any unrealized gains or losses are recorded
              in net earnings.
      
              The following is the basis of classification and measurement of the
              Company's financial instruments:
      
                 -  Cash is classified as held-for-trading and is measured at fair
                    value;
                 -  Accounts receivable and loan receivable are classified as loans
                    and receivables and recorded at cost, which at initial
                    measurement corresponds to fair value. After initial fair value
                    measurement, they are measured at amortized cost; and
                 -  Accounts payable and accrued liabilities are classified as
                    other financial liabilities. They are initially measured at
                    fair value and, if necessary, subsequent revaluations are
                    recorded at amortized cost.
      
          2   CHANGES IN ACCOUNTING POLICIES
      
              Goodwill and Intangible Assets
      
              As required by The Canadian Institute of Chartered Accountants
              ("CICA"), on January 1, 2009, the Company adopted CICA Handbook
              Section 3064, Goodwill and Intangible Assets, which establishes
              standards for the recognition, measurement, presentation and
              disclosure of goodwill and intangible assets. Application of this
              pronouncement had no impact on the reported results of operations.
      
              International Financial Reporting Standards ("IFRS")
      
              Commencing in the first quarter of 2011, the Company's financial
              statements will be prepared in accordance with IFRS, with 2010
              comparative figures and the January 1, 2010 opening balance sheet
              restated to conform with IFRS, along with reconciliations from GAAP
              to IFRS, as per the guidance provided in IFRS 1, First-Time Adoption
              of International Financial Reporting Standards.
      
              As part of its transition to IFRS, the Company has developed an
              implementation plan which includes an analysis of accounting
              differences between GAAP and IFRS and the assessment of the expected
              impact of the accounting differences on its financial statements. The
              Company continues to assess the IFRS component evaluation for those
              areas of the financial statements that have identified accounting
              differences between GAAP and IFRS. As part of its IFRS implementation
              plan, the Company will continue to review the impact on its business
              activities, its disclosure and internal controls over financial
              reporting and its financial reporting systems.
      
          3   RISK MANAGEMENT
      
              Financial risk management
      
              In the normal course of business, the Company is exposed to a number
              of financial risks that can affect its operating performance. These
              risks are: credit risk, liquidity risk and market risk. The Company's
              overall risk management program and prudent business practices seek
              to minimize any potential adverse affects on the Company's financial
              performance.
      
              (i) Credit risk
      
              Accounts receivable - the Company licenses its products to
              distribution partners in major markets. The credit risk associated
              with the accounts receivable pursuant to these agreements is
              evaluated during initial negotiations and on an ongoing basis. There
              have been no events of default under these agreements. As of
              December 31, 2009, no accounts receivable balances were considered
              impaired or past due.
              Loan receivable - the loan receivable is repaid in annual instalments
              over a five year period, with one instalment remaining as at
              December 31, 2009, which was received subsequent to year end.
      
              (ii) Liquidity risk
      
              The Company has no long term debt with specified repayment terms.
              Accounts payable and accrued liabilities are settled in the regular
              course of business, based on negotiated terms with trade suppliers.
              All components of the balance of $1,570 as at December 31, 2009 are
              expected to be settled in less than one year. The carrying value of
              the balances approximate their fair value as the impact of
              discounting is not significant.
      
              (iii) Market risk
      
              Currency risk - the majority of the Company's revenue and a portion
              of its expenses are denominated in US currency. The accounts
              receivable balance at December 31, 2009 includes a total of US$864
              and accounts payable and accrued liabilities includes a total of
              US$882. There is no currency hedging program currently in place due
              to the relatively short time frame for settlement of these balances.
              A 10% change in the US/CDN exchange rate on the net December 31, 2009
              balances would have had a $2 impact on net income.
      
              Capital risk management
      
              Shareholders' equity is managed as the capital of the Company. The
              Company's objective when managing capital is to safeguard its ability
              to continue as a going concern in order to provide returns for
              shareholders and to maintain an optimal capital structure to minimize
              the cost of capital. In order to maintain or adjust the capital
              structure, the Company may issue new common shares from time to time.
      
          4   PROPERTY AND EQUIPMENT
      
              The following is a summary of property and equipment as at
              December 31, 2009:
      
                                         December 31, 2009       December 31, 2008
              ---------------------------------------------------------------------
                                               Accumulated             Accumulated
                                        Cost  Amortization      Cost  Amortization
              ---------------------------------------------------------------------
              Computer equipment     $   106       $    97   $   101       $    79
              Computer software           38            34        35            24
              Furniture and fixtures     126            85       126            58
              Leasehold improvements      67            35        67            21
                                     ----------------------------------------------
                                         337       $   251       329       $   182
              Accumulated
               amortization             (251)                   (182)
              ---------------------------------------------------------------------
                                     $    86                 $   147
              ---------------------------------------------------------------------
              ---------------------------------------------------------------------
      
          5   LOAN RECEIVABLE
      
              On February 28, 2005, the Company completed the sale of its
              wholly-owned pharmaceutical research services business, Pharma Medica
              Research Inc. (Pharma Medica). Consideration consisted of a cash
              payment of $14,000 and a deferred payment of $4,000. The deferred
              payment is non-interest bearing and is repayable in annual
              instalments of $800 over a five year period. As the deferred payment
              is non-interest bearing, it was originally recorded at its fair value
              of $3,112 based on a discount rate of 9%. Imputed interest of $87 has
              been recorded on this deferred payment during the year ended
              December 31, 2009 ($136 during the year ended December 31, 2008). In
              accordance with the terms of the deferred payment agreement, $188 of
              clinical services purchased from Pharma Medica were offset against
              the annual instalment received on January 30, 2009. The final
              instalment of $800 was received on January 30, 2010.
      
          6   INTANGIBLE ASSETS
      
              During fiscal 2001, the Company entered into certain agreements with
              Galephar Pharmaceutical Research Inc. ("Galephar") for the rights to
              package, test, obtain regulatory approvals and market certain
              products in various countries around the world. In accordance with
              the terms of the agreements, the Company has acquired these
              intangible rights through an investment in three separate series of
              preferred shares of Galephar. The Company may be required to pay
              additional amounts to Galephar in respect of the CIP-ISOTRETINOIN and
              CIP-TRAMADOL ER intangible rights of up to $1,465 (US$1,400) if
              certain future milestones are achieved as defined in the agreements.
              These additional payments will be made in the form of additional
              Galephar preferred share purchases. The recoverability of these
              intangible rights is dependant upon sufficient revenues being
              generated from the related products currently under development and
              commercialization. The Company is currently amortizing the intangible
              rights related to CIP-FENOFIBRATE and CIP-ISOTRETINOIN.
      
              With regard to CIP-FENOFIBRATE, in July 2007 the Company entered into
              a licensing and distribution agreement with Kowa Pharmaceuticals
              America, Inc. ("Kowa"), under which Kowa was granted the exclusive
              right to market, sell and distribute Lipofen in the United States.
              The Company received an up-front licensing payment of US$2 million
              and, under the terms of the agreement, could receive additional
              milestone payments of up to US$20 million based on the achievement of
              certain net sales targets. The Company also receives a royalty based
              on a percentage of net sales. These elements are reflected in
              licensing revenue, net of product-related expenses and amounts due to
              Galephar, the Company's technology partner. During the second quarter
              of 2009, the Company received a US$1 million payment from Kowa in
              return for the partial waiver of a non-compete covenant in the
              licensing and distribution agreement for Lipofen. The waiver relates
              to a combination product and not a fenofibrate-only formulation that
              would compete with Lipofen. Under the revised agreement, the Company
              will receive additional payments should Kowa be successful in
              commercializing its combination product and it includes provisions to
              ensure Lipofen revenue is not impacted once the combination product
              reaches the market. Revenue is being recognized on this payment using
              a straight-line amortization method over the estimated commercial
              life of the product. After product-related expenses are deducted,
              approximately 50% of all milestone and royalty payments received by
              the Company under the agreement will be paid to Galephar. Lipofen was
              launched in the U.S. market in 2007.
      
              In August 2008, the Company entered into a development and supply
              agreement with Ranbaxy Pharmaceuticals Inc. ("Ranbaxy") under which
              Ranbaxy was granted the exclusive right to market, sell and
              distribute CIP-ISOTRETINOIN in the United States. Under the terms of
              the agreement, the Company received an up-front licensing payment of
              US$1 million and could receive additional pre- and
              post-commercialization milestone payments of up to US$23 million,
              based on the achievement of certain milestone targets. Once the
              product is successfully commercialized, the Company will also receive
              a royalty based on a percentage of net sales. In addition, Ranbaxy
              will reimburse the Company for all costs associated with the clinical
              studies required by the FDA to secure NDA approval, up to a
              predetermined cap. Any additional development costs associated with
              initial FDA approval will be shared equally. The Company is
              responsible for all product development activities, including
              management of the clinical studies required by the FDA to secure NDA
              approval and is also responsible for product supply and
              manufacturing, which will be fulfilled by Galephar. During 2009, a
              payment of $122 was made to acquire additional intangible rights for
              CIP-ISOTRETINOIN. After product-related expenses are deducted,
              approximately 50% of all milestone and royalty payments received by
              the Company under the agreement will be paid to Galephar.
      
              The following is a summary of intangible assets as at December 31,
              2009:
      
                                         December 31, 2009       December 31, 2008
              ---------------------------------------------------------------------
                                               Accumulated             Accumulated
                                        Cost  Amortization      Cost  Amortization
              ---------------------------------------------------------------------
              CIP-FENOFIBRATE        $ 2,332       $ 1,865   $ 2,332       $ 1,398
              CIP-ISOTRETINOIN         1,579           274     1,457             -
              CIP-TRAMADOL ER          1,735             -     1,735             -
                                     ----------------------------------------------
                                       5,646       $ 2,139     5,524       $ 1,398
              Accumulated
               amortization           (2,139)                 (1,398)
              ---------------------------------------------------------------------
                                     $ 3,507                 $ 4,126
              ---------------------------------------------------------------------
              ---------------------------------------------------------------------
      
          7   SHARE CAPITAL
      
              Authorized share capital
      
              The authorized share capital consists of an unlimited number of
              preference shares, issuable in series, and an unlimited number of
              voting common shares.
      
              Issued share capital
      
              There have been no changes in the Company's share capital during the
              period from December 31, 2007 to December 31, 2009. The following is
              a summary of the Company's share capital as at December 31, 2009:
      
                                                          Number of
                                                        common shares       Amount
                                                        (in thousands)         $
      
              Balance - December 31, 2009                      24,055       49,948
                                                       ----------------------------
                                                       ----------------------------
      
              Stock option plan
      
              The following is a summary of the changes in the stock options
              outstanding from December 31, 2007 to December 31, 2009:
      
                                                                          Weighted
                                                                           average
                                                          Number of       exercise
                                                           options          price
                                                        (in thousands)        $
      
              Balance - December 31, 2007                         998         3.36
                Granted in 2008                                   483         0.78
                Expired or cancelled in 2008                     (105)        2.55
                                                        --------------
              Balance - December 31, 2008                       1,376         2.51
      
                Granted in 2009                                   224         0.60
                Expired in 2009                                   (20)        4.33
                                                        --------------
              Balance - December 31, 2009                       1,580         2.22
                                                        --------------
                                                        --------------
      
              At December 31, 2009, 806,974 options were fully vested and
              exercisable (540,482 at December 31, 2008).
      
              During 2009, the Company issued 224,375 stock options under the
              employee and director stock option plan, with exercise prices of
              $0.61 and $0.55, 25% of which vest on either February 20 or
              November 6 of each year for the next four years, commencing in 2010,
              and all of which expire in 2019. Total compensation cost for these
              stock options is estimated to be $125. This cost will be recognized
              over the vesting period of the stock options.
      
              The stock options issued during 2009 were valued using the
              Black-Scholes option pricing model with the following assumptions:
      
                 Risk-free interest rate                           2.87% and 3.52%
                 Expected life                                            10 years
                 Expected volatility                                 106% and 114%
                 Expected dividend                                             Nil
      
              The following is a summary of the outstanding options as at
              December 31, 2009:
                                    Exercise
                 Expiry date          price       Number of options (in thousands)
                                                 ----------------------------------
                                        $         Vested      Unvested       Total
      
                 January 11, 2012      1.09          125            -          125
                 September 17, 2014    2.35          125            -          125
                 March 23, 2016        4.12          150           50          200
                 June 28, 2016         4.00          135           45          180
                 September 13, 2016    2.90           52           17           69
                 March 9, 2017         3.90          112          112          224
                 February 28, 2018     1.05           53          160          213
                 November 7, 2018      0.45           45          135          180
                 December 3, 2018      0.50           10           30           40
                 February 20, 2019     0.61            -          204          204
                 November 6, 2019      0.55            -           20           20
                                                 ----------------------------------
                                                     807          773        1,580
                                                 ----------------------------------
                                                 ----------------------------------
      
          8   CONTRIBUTED SURPLUS
      
              The following is a summary of the changes in contributed surplus from
              December 31, 2007 to December 31, 2009:
      
                                                                           Amount
                                                                              $
      
              Balance - December 31, 2007                                   31,032
                Stock-based compensation expense in 2008                       581
                                                                          ---------
              Balance - December 31, 2008                                   31,613
      
                Stock-based compensation expense in 2009                       655
                                                                          ---------
              Balance - December 31, 2009                                   32,268
                                                                          ---------
                                                                          ---------
      
          9   RESEARCH AND DEVELOPMENT
      
              A total of $5,381 of research and development costs were incurred in
              2009 ($2,239 in 2008). The research and development expense reflected
              in the Statement of Operations is presented net of Ontario Innovation
              Tax Credit ("OITC") program credits of $53 ($440 in 2008) for
              qualifying research and development expenditures and an amount of
              $4,372 reimbursed by Ranbaxy ($496 in 2008). Under the terms of the
              agreement with Ranbaxy, research and development costs incurred for
              clinical studies required by the FDA to secure approval for
              CIP-ISOTRETINOIN are reimbursed to the Company and as a result, there
              was a nil impact to research and development expense with respect to
              these costs.
      
          10  INCOME TAXES
      
              The provision for income taxes differs from the amount computed by
              applying the statutory income tax rate to the loss for the year. The
              sources and tax effects of the differences are as follows:
      
                                                                For the year ended
                                                                    December 31,
                                                                 2009         2008
                                                                   $            $
      
              Statutory income tax rate of 33% applied
               to loss for the year (2008 - 33.5%)               (896)      (1,082)
              Permanent differences                               192           57
              Change in enacted income tax rates and other
               items                                            3,382         (599)
              Change in valuation allowance                    (2,678)       1,624
                                                            -----------------------
              Provision for income taxes                            -            -
                                                            -----------------------
                                                            -----------------------
      
              The significant components of future income tax assets are summarized
              as follows:
      
                                                                       As at
                                                                    December 31,
                                                                 2009         2008
                                                                   $            $
      
              Non-capital losses                                9,811       10,776
              Excess of tax value of property and equipment
               over book value                                     59           49
              SR&ED expenditure pool                            3,097        3,466
              Excess of tax value of intangible assets over
               book value                                       6,194        7,581
              Benefit of investment tax credits                 2,038        2,057
              Capital losses                                      177           93
              Deductible share issue costs                         55          127
              Ontario harmonization tax credit                    120            -
              Other temporary differences                         407          487
                                                            -----------------------
                                                               21,958       24,636
              Valuation allowance                             (21,958)     (24,636)
                                                            -----------------------
                                                                    -            -
                                                            -----------------------
                                                            -----------------------
      
              The Company has non-capital loss carry forwards of $39,300 as at
              December 31, 2009 that expire in varying amounts from 2014 to 2029.
      
              The Company has Scientific Research and Experimental Development
              ("SR&ED") expenditures of $12,400 which can be carried forward
              indefinitely to reduce future years' taxable income.
      
              The Company has approximately $2,700 of investment tax credits on
              SR&ED expenditures that are available to be applied against federal
              taxes otherwise payable in future years and expire in varying amounts
              from 2012 to 2029.
      
          11  LOSS PER SHARE
      
              Loss per share is calculated using the weighted average number of
              shares outstanding. The weighted average number of shares outstanding
              for the year ended December 31, 2009 and the year ended December 31,
              2008 was 24,054,878.
      
              As the Company had a loss for each of the periods presented, basic
              and diluted loss per share are the same because the exercise of all
              stock options would have an anti-dilutive effect.
      
          12  SUPPLEMENTAL CASH FLOW INFORMATION
      
              The following is a summary of the changes in non-cash operating
              items:
      
                                                                For the year ended
                                                                    December 31,
                                                                 2009         2008
                                                                   $            $
      
              Accounts receivable                                (455)         884
              Income taxes receivable                               6          122
              Prepaid expenses and other current assets           (77)        (324)
              Accounts payable and accrued liabilities            392          119
              Deferred revenue                                    114          189
                                                            -----------------------
                                                                  (20)         990
                                                            -----------------------
                                                            -----------------------
      
          13  SEGMENTED INFORMATION
      
              The Company's operations are categorized into one industry segment,
              being specialty pharmaceuticals. All of the Company's assets,
              including capital and intangible assets, are in Canada, while all
              licensing revenue is derived from the United States.
          
      

      %SEDAR: 00020415E

      For further information: Craig Armitage, Investor Relations, The Equicom Group, (416) 815-0700 ext 278, (416) 815-0080 fax, [email protected]; Larry Andrews, President and CEO, Cipher Pharmaceuticals, (905) 602-5840 ext 324, (905) 602-0628 fax, [email protected]

      Modal title

      Organization Profile

      Cipher Pharmaceuticals Inc.

        Also from this source

      • Cipher Pharmaceuticals Reports Third Quarter 2026 Results

      • Cipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference Call

      • Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.